TCM, Western medicine collaboration could help tackle chronic GI disorders, experts say
Singapore-based Nanyang Technological University Chinese Medicine and Biomedical Sciences director Associate Prof Dr Linda Zhong said that while some GI disorders can be treated with Western medicine, some may be more difficult to address, and this is where TCM could help.
"There have been academic papers written about TCM and its positive effect on patients with certain disorders.
"Acupuncture, for instance, can help with indigestion and constipation, which is recognised by specialists," she told the press after attending the three-day 6th South-East Asia Gastroneuro-Motility Association (Seagma) scientific conference on gastroenterology motility diseases here on Sunday (July 13).
"We also have a lot of other research on Chinese medicine that can help, with some of these available in the market.
"We hope to have more collaboration with Western medicine to see if we can have breakthroughs in treatment for more functional digestive disorders," she added.
Singapore National University Medicine Department clinical lecturer Prof Dr Kewin Siah said that patients have often had to resign themselves to live with chronic GI disorders despite consulting specialists.
"Despite getting... second opinions, some are unable to get an answer from their doctors as to what ails them.
"But things... should not be (like this)," he said, adding that prolonged battles with GI disorders can also impact some patients' mental health.
"There can be certain limitations with Western medicine, and likewise with TCM, so we want to see if a collaboration can result in new findings," he added.
Ipoh-based gastroenterologist Datuk Dr Andrew Chua, who is Seagma president, said a collaboration between Western medicine and TCM to treat functional GI disorders was still new to Malaysia.
"TCM should no longer merely be a complementary treatment method.
"We are trying to advance it and to introduce it into (Western) medical practice to provide treatment," he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
9 hours ago
- The Sun
Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences real estate market on the Chinese mainland
HONG KONG SAR - Media OutReach Newswire - 1 August 2025 - Cushman & Wakefield, a leading global real estate services firm, today released its Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences real estate market on the Chinese mainland report. It is based on in-depth interview surveys we conducted on professionals active in the life sciences sector on the Chinese mainland. The life sciences industry on the Chinese mainland is undergoing a transformative phase, driven by progressive policies, groundbreaking innovations, the emergence of influential life sciences companies, and strategic regional development. This report delves into the latest trends shaping the sector. Policy Landscape – National and Local Catalysts Reforms enacted in 2024-2025 have significantly accelerated sector development. Nationally, China relaxed restrictions on foreign investment in gene and cell therapy and allowed the establishment of wholly foreign-owned hospitals in key cities. Regulatory incentives – such as data protection and marketing exclusivity – have improved market access for innovative drugs. Locally, cities like Beijing, Shanghai, Shenzhen, Guangzhou, and Suzhou are rolling out targeted subsidies, fast-track approvals, and ecosystem-building programmes that directly benefit biotech development. Recent national policy initiatives on the Chinese mainland Industry Innovation and Company Growth Chinese life sciences companies are moving beyond generic drug manufacturing toward innovative therapies. Firms like Akeso, BeiGene, Gracell, and Legend Biotech are now global players, leading in CAR-T, bispecific antibodies, and AI-assisted R&D. These companies are not only commercialising cutting-edge treatments but also attracting international investment and licensing agreements, reinforcing the Chinese mainland's global relevance in life sciences. Real Estate Development and Regional Hubs Innovation hubs such as Suzhou BioBAY, Zhangjiang Hi-Tech Park (Shanghai), and the Bioisland Innovation Centre (Guangdong) are central to regional clustering. These hubs offer end-to-end support, including shared labs, venture capital access, GMP-compliant facilities, and proximity to academic and clinical networks. The rise of second-tier innovation cities like Chengdu and Ningbo further expands growth corridors. The 'R&D + Manufacturing + Service' ecosystem Source: Cushman & Wakefield Research Landlord Perspectives – Evolving Real Estate Models Real estate developers and landlords are adapting to sector-specific requirements through asset-light models, flexible leasing, and high-specification lab and production space. Tier-1 cities face saturation, but central and western regions exhibit healthy demand. Developers are incorporating advanced sustainability and compliance features to meet growing regulatory and ESG expectations, particularly in GMP and cleanroom environments. Digitalisation, environmental policies, and differentiated tenant strategies are shaping performance. Operators now focus on integrated ecosystems with platforms that link tenants to R&D services, policy benefits, and technology partners. Occupier Perspectives – Growth, Innovation, and Challenges Life sciences occupiers are navigating regulatory reform, rising compliance demands, and intensified market competition. Many are localising production and R&D, leveraging regional subsidies, and investing in AI-powered innovation platforms. Occupiers seek flexibility, proximity to talent and infrastructure, and co-located R&D and manufacturing to support accelerated innovation and operational agility. In real estate, demand is strongest for GMP-certified labs, modular production facilities, and shared innovation platforms. Occupiers emphasise location advantages, sustainability certifications (e.g., LEED, WELL), and integration into clusters that enable faster time-to-market. Tony Su, Managing Director, National Head of Industrial & Logistics Property Services, China, said, 'Life sciences business parks on the Chinese mainland demonstrated clear regional differentiation, highlighting opportunities for strategic positioning. While Tier-1 cities saw more moderate performance due to broader macroeconomic factors and abundant supply, core cities in central and western regions recorded healthy occupancy rates, underpinned by strong industrial clustering and increasingly sophisticated ecosystems – contributing to steady growth in asset value.' Johnathan Wei, President, Project & Occupier Services, China, said, 'Several interviewed life sciences companies on the Chinese mainland achieved revenue growth supported by innovative products and favourable policy tailwinds. While overall growth remained modest for many, a select group reported strong performance, highlighting opportunities for differentiation'. Andrew Chan, Managing Director, Head of Valuation & Advisory Services, Greater China, said,' Looking ahead to 2025 and beyond, growth opportunities lie in AI-driven drug discovery, personalised medicine, advanced therapeutics (CGT, RNA), and green-certified facilities. Government policies continue to support innovation through fast-track approvals, rare disease funding, and subsidies aligned with dual-carbon and ESG goals'. Shaun Brodie, Head of Research Content, Greater China, 'Life sciences real estate is shifting from generic parks to specialised, digitally enabled campuses with high compliance and flexibility. Investment strategies increasingly emphasise long-term partnerships, collaborative operating models, and digital infrastructure. Both landlords and occupiers express cautious optimism, with strategic differentiation and regional targeting seen as keys to unlocking future value'. Please click here to download the full report.
The Star
17 hours ago
- The Star
China courier puts sick daughter in delivery box at work to save on childcare
A Chinese mother who delivered food with her 4-year-old sick daughter inside a meal-carrying box so that she could look after her has received sympathy online. The woman, surnamed Zhu, and her child were caught on camera by an online influencer in eastern China's Anhui province.
Malaysian Reserve
a day ago
- Malaysian Reserve
BioLab Holdings, Inc. Launches Its Largest Clinical Trial to Date Evaluating Human Placental Membrane Products
Study Will Compare Four Amnion-Based Therapies Plus Standard of Care to Standard of Care Alone in Chronic Wound Management PHOENIX, July 31, 2025 /PRNewswire/ — BioLab Holdings, Inc., a Phoenix-based medical manufacturer specializing in regenerative wound care, has initiated its most comprehensive clinical trial to date. The multicenter, prospective, randomized controlled study will evaluate the efficacy of four human placental membrane (HPM) products in combination with standard of care (SOC) compared to SOC alone in the treatment of nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). The trial, formally titled 'A Multicenter, Prospective, Randomized Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers (BIOCAMP),' will enroll 650 subjects across up to 30 clinical sites nationwide. 'This study represents a major milestone in our commitment to advancing wound care through rigorous clinical research,' said Dr. Marshall Medley, chief medical officer at BioLab. 'By evaluating our full suite of amnion-based products in a real-world setting, we aim to provide clinicians with robust data to guide treatment decisions for patients with chronic wounds.' Participants will be randomized to receive one of four BioLab products—Tri-Membrane Wrap™ (HPM-1), Membrane Wrap™ (HPM-2), Membrane Wrap-Lite™ (HPM-3), or Membrane Wrap-Hydro™ (HPM-4)—in addition to SOC, or SOC alone. Treatments will be applied weekly for up to 12 weeks or until complete wound closure is achieved and confirmed two weeks later. Optional weekly visits will allow for dressing changes in both study arms. The study is designed to capture real-world clinical outcomes and support the growing body of evidence for the use of placental-derived allografts in chronic wound management. For more information on BioLab Holdings, Inc. and its regenerative wound care solutions, visit About BioLab Holdings, Holdings, Inc. is a Phoenix-based medical manufacturer focused on wound healing and regenerative medicine. Its product portfolio includes Membrane Wrap Lite™, Tri-Membrane Wrap™, Membrane Wrap™ and Membrane Wrap – Hydro™, all derived from human amniotic membrane. These minimally manipulated allografts are designed to preserve the tissue's natural properties and support healing. BioLab is committed to delivering safe, high-quality products through innovation, education and exceptional customer service. Learn more at Contact: Kwyn LowePhone: 406.314.5120Email: kwyn@
